New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Case Western Reserve University School of Medicine

COVID-19 disease in children seems to be less severe than adults based on the current literature and our personal experience at Children's Hospitals. Among adults, the coagulopathy is beginning to be described with elevated inflammatory markers and other markers of coagulation activation, including ...

What dose do you use to palliate multiple myeloma in a vertebral body?

1
5 Answers

Mednet MemberInvited Expert
Radiation Oncology · UCSD Radiation Oncology

For ISS Stage 1 MM patients who are going to have an OS of over 10 years, I generally prefer a more protracted regimen of 25 Gy in 10 fractions for improved durability of pain control. I typically only treat the symptomatic VB only and use inverse planning. If there is gross epidural disease or cord...

How do you approach palliative RT dose selection to skeletal lesions in patients with Myeloma who are actively receiving or likely to need systemic therapy?

2 Answers

Mednet MemberInvited Expert
Radiation Oncology · Harvard Radiation Oncology Program

Multiple myeloma patients with painful bone disease often present a unique constellation of clinical characteristics, such as extensive skeletal involvement, longer life expectancies, and many prior or anticipated systemic treatments. Some key features influencing my choice of radiation dose and sch...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you approach immediate management of paraspinal extramedullary hematopoiesis in patients with transfusion-dependent thalassemia when lesions are enlarging or causing neurologic symptoms?

1
1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

In general, the goal of transfusion therapy in transfusion-dependent thalassemia (TDT) is to suppress ineffective erythropoiesis. It is the rationale for maintaining a higher pre-transfusion hemoglobin level, at 9.5-10.5 g/dl, well above the general threshold for PRBC transfusion used in oncology pa...

Are there still clinical situations in which you deliberately treat patients with a DOAC besides apixaban?

2
6 Answers

Mednet MemberInvited Expert
General Internal Medicine · University of Chicago

Thank you for your question. Apixaban has been my preferred agent for a long time for patients requiring therapeutic anticoagulation. Apixaban’s lower bleeding risk was shown prior to and now has additional evidence to support this with the COBRRA trial. The risk is also ameliorated by the safety in...

Would you continue venetoclax indefinitely beyond standard fixed-duration therapy with ven/obinutuzumab for a patient with high-risk TP53-mutated/del17p CLL refractory to initial acalabrutinib with ALC doubling time < 6 months without BTK resistance mutations?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center

This patient has covalent BTKi (cBTKi) resistance without a resistance mutation and was transitioned to venetoclax + obinutuzumab. Overall, this patient is not going to do well and in addition to initiating therapy, the provider should refer this patient to a CLL expert provider for co-management. T...

Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP, similar to R-miniCHOP?

2
2 Answers

Mednet MemberInvited Expert
Hematology · Rutgers Cancer Institute/Rutgers Robert Wood Johnson Medical School

I have utilized a dose-reduced approach for Pola-R-CHP for patients who are elderly, whom I would normally treat with R-miniCHOP, based on the early safety data from the POLAR BEAR trial. This randomized trial compared pola-r-miniCHP to R-miniCHOP in patients &gt;80 years of age or &gt;/=75 with comorbid ...

Can the Fishbane reaction happen with an initial test dose of low molecular weight iron dextran, i.e., infed?

1 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

Yes, the fishbane reaction can occur with no prior exposure. This applies to any of the formulations. The reaction is more frequent with generic ferumoxytol, which should be avoided. Otherwise, the incidence is equally frequent. It is definitely not unique to iron dextran, as the question implies. W...

How would you approach anticoagulation for a patient with acute bilateral pulmonary emboli related to malignancy, but with a concomitant cavitary lung mass experiencing episodic, small-volume hemoptysis?

4
3 Answers

Mednet MemberInvited Expert
Hospital Medicine · Emory University Hospital

This is an interesting question to which we need to apply the art of medicine, weighing the risks and benefits of treatment. The major fatal events in this exact scenario are: Recurrent PE from undertreatment. Sudden massive hemoptysis after aggressive anticoagulation. The physician's management s...

For atrial fibrillation patients with high risk of CVA who cannot tolerate full dose AC due to bleeding, do you consider low dose/extended dosing anticoagulation even if they do not meet age/GFR criteria for a dose reduction, if Watchman is not readily available as an option?

1
1 Answers

Mednet MemberInvited Expert
Cardiology · Lankenau Heart Group

Most drugs, including anticoagulants, have a dose-response. Therefore, one could argue that even though DOACs were not studied at low doses, except in defined sub-groups such as the very elderly, using such a dose in other situations may have some benefit. The problem is that without data, we simply...